These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oncogenic KRAS signalling in pancreatic cancer. Eser S; Schnieke A; Schneider G; Saur D Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884 [TBL] [Abstract][Full Text] [Related]
6. KRAS above and beyond - EGFR in pancreatic cancer. Siveke JT; Crawford HC Oncotarget; 2012 Nov; 3(11):1262-3. PubMed ID: 23174662 [No Abstract] [Full Text] [Related]
7. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025 [TBL] [Abstract][Full Text] [Related]
8. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792 [TBL] [Abstract][Full Text] [Related]
9. The KRAS-PDEδ interaction is a therapeutic target. Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364 [TBL] [Abstract][Full Text] [Related]
10. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186 [TBL] [Abstract][Full Text] [Related]
11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115 [TBL] [Abstract][Full Text] [Related]
12. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Son J; Lyssiotis CA; Ying H; Wang X; Hua S; Ligorio M; Perera RM; Ferrone CR; Mullarky E; Shyh-Chang N; Kang Y; Fleming JB; Bardeesy N; Asara JM; Haigis MC; DePinho RA; Cantley LC; Kimmelman AC Nature; 2013 Apr; 496(7443):101-5. PubMed ID: 23535601 [TBL] [Abstract][Full Text] [Related]
13. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice. Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451 [TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity for Kras Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996 [TBL] [Abstract][Full Text] [Related]
15. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Zhang YF; Li Q; Huang PQ; Su T; Jiang SH; Hu LP; Zhang XL; Sun Y; Pan H; Yang XM; Li J; Gai YZ; Zhu L; Yao LL; Li DX; Sun YW; Zhang ZG; Liu DJ; Zhang YL; Nie HZ Oncogene; 2022 Feb; 41(8):1203-1215. PubMed ID: 35082383 [TBL] [Abstract][Full Text] [Related]
16. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400 [TBL] [Abstract][Full Text] [Related]
17. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Hill R; Calvopina JH; Kim C; Wang Y; Dawson DW; Donahue TR; Dry S; Wu H Cancer Res; 2010 Sep; 70(18):7114-24. PubMed ID: 20807812 [TBL] [Abstract][Full Text] [Related]
18. Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations. Sawai Y; Kodama Y; Shimizu T; Ota Y; Maruno T; Eso Y; Kurita A; Shiokawa M; Tsuji Y; Uza N; Matsumoto Y; Masui T; Uemoto S; Marusawa H; Chiba T Cancer Res; 2015 Aug; 75(16):3292-301. PubMed ID: 26113087 [TBL] [Abstract][Full Text] [Related]
19. Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. Søreide K; Sund M Cancer Lett; 2015 Jan; 356(2 Pt A):281-8. PubMed ID: 24704294 [TBL] [Abstract][Full Text] [Related]
20. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D Cancer Cell; 2013 Mar; 23(3):406-20. PubMed ID: 23453624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]